VXRT Live-Signale | Maximieren Sie Profite mit Getagraph.com

VERKAUFEN 110774 min ago

@ $1.235

Ausgestellt: 12 Feb 2024 @ 21:35

Rendite: -42.90%

Vorheriges Signal: Feb 12 - 20:01

Vorheriges Signal: Kaufen

Rendite: 2.06 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 20:48):

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform...

Stats
Tagesvolumen	703 792
Durchschnittsvolumen	1.95M
Marktkapitalisierung	124.71M
EPS	$0 ( 2024-03-14 )
Nächstes Ertragsdatum	( $-0.160 ) 2024-05-02
Last Dividend	$12.19 ( 2012-11-09 )
Next Dividend	$0 ( N/A )
P/E	-1.240
ATR14	$0.00200 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-28	Tucker Sean	Buy	0
2024-03-28	Tucker Sean	Sell	3 902	Common Stock
2024-03-28	Cummings James F.	Sell	3 292	Common Stock
2024-03-18	Tucker Sean	Buy	90 000	Common Stock
2024-03-18	Tucker Sean	Buy	410 000	Stock Option (right to buy)

INSIDER POWER
94.60
Last 95 transactions
Buy: 10 890 181 \| Sell: 279 805

Volumen Korrelation

Lang: -0.06 (neutral)

Kurz: 0.56 (weak)

Signal:(44.816) Neutral

Vaxart Inc Korrelation

10 Am meisten positiv korreliert
LYEL	0.934
LYRA	0.93
TCRT	0.92
FATE	0.92
WISA	0.915
GROM	0.914
AFMD	0.914
ARQQ	0.914
GRNA	0.913
AVO	0.912

10 Am meisten negativ korreliert
LRFC	-0.93
STAY	-0.928
GLLI	-0.907
IBEX	-0.905
XOMAO	-0.899
XOMAP	-0.898
CHPM	-0.898
BCOR	-0.895
MNKD	-0.893
CIIG	-0.891

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Vaxart Inc Korrelation - Währung/Rohstoff

0.00
( neutral )

-0.13
( neutral )

Vaxart Inc Finanzdaten

Annual	2023
Umsatz:	$7.38M
Bruttogewinn:	$2.88M (39.02 %)
EPS:	$-0.570

FY	2023
Umsatz:	$7.38M
Bruttogewinn:	$2.88M (39.02 %)
EPS:	$-0.570

FY	2022
Umsatz:	$107 000
Bruttogewinn:	$-3.16M (-2 953.27 %)
EPS:	$-0.840

FY	2021
Umsatz:	$892 000
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.580

Financial Reports:

No articles found.

Vaxart Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Vaxart Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$12.19	2012-11-09
Last Dividend	$12.19	2012-11-09
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$12.19	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-29)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2012	$12.19	9.77%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-14.41	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.898	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-1.085	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.32	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.11	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.53	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0994	-1.500	8.34	-10.00	[0 - 0.6]
interestCoverageTTM	-57.60	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.459	2.00	-0.153	-0.306	[0 - 30]
freeCashFlowPerShareTTM	-0.471	2.00	-0.236	-0.471	[0 - 20]
debtEquityRatioTTM	0.158	-1.500	9.37	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.196	1.000	-0.0722	-0.0722	[0.2 - 0.8]
operatingProfitMarginTTM	-14.56	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-7.72	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.0623	0.800	-2.92	-2.33	[0.5 - 2]
Total Score				-1.818

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-1.321	1.000	-0.234	0	[1 - 100]
returnOnEquityTTM	-1.085	2.50	-8.46	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.471	2.00	-0.157	-0.471	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.459	2.00	-0.153	-0.306	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-12.31	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.59

Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

Echtzeitaktualisierungen für Vaxart Inc [VXRT]

Upcoming Earnings Alert

Vaxart Inc Dividend Information - No Dividend Player

Dividend Commentary

Top 10 dividend Companies for NASDAQ

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)